Targeted therapies in cancer

BioDrugs. 2010 Apr 1;24(2):77-88. doi: 10.2165/11530830-000000000-00000.


Recent advances in understanding the biologic mechanisms underlying cancer development have driven the design of new therapeutic approaches, termed 'targeted therapies', that selectively interfere with molecules or pathways involved in tumor growth and progression. Inactivation of growth factors and their receptors on tumor cells as well as the inhibition of oncogenic tyrosine kinase pathways and the inhibition of molecules that control specific functions in cancer cells constitute the main rational bases of new cancer treatments tailored for individual patients. Small-molecule inhibitors and monoclonal antibodies are major components of these targeted approaches for a number of human malignancies. As the studies of the bio-molecular features of cancer progress, new exciting strategies have arisen, such as targeting cancer stem cells that drive tumor relapses or the selective induction of apoptosis in malignant cells. This article primarily focuses on the biologic bases of the new cancer drugs and summarizes their mechanisms of action, the clinical evidence of their anti-cancer effectiveness as well as the rationale for their use in clinical practice.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Drug Delivery Systems / methods*
  • Drugs, Investigational / therapeutic use*
  • Humans
  • Models, Biological
  • Neoplasms / drug therapy*
  • Neoplasms / therapy*
  • Neoplastic Stem Cells / drug effects
  • Signal Transduction / drug effects


  • Antineoplastic Agents
  • Drugs, Investigational